With @READDI_Inc's broad-spectrum, small molecule antivirals, the world can avoid another catastrophic viral outbreak.
A harsh truth: The world economy never recovered from the COVID-19 pandemic /via @globeandmail https://t.co/a1QqETmi4N
@READDI_Inc has not forgotten. We are developing antivirals that work broadly against all viruses in virus families of pandemic potential.
We’ve forgotten pandemic prep https://t.co/3EcnHhv1qj via @politico
@READDI_Inc is excited to be partnering with @SASsoftware on AI and machine-learning fueled drug discovery for antivirals against virus families of pandemic potential. https://t.co/HtjWkoO8pY via @YouTube
@READDI_Inc was pleased to contribute to this important report, highlighting progress made in 2023 and work planned in 2024. Learn more: https://t.co/jK610NxBqU
@READDI_Inc is developing antiviral treatments now to become the standard of care for the next unknown viral threat, also known as Disease X. Learn more about how READDI is contributing to the R&D pipeline for pandemic pathogens. https://t.co/I5SQY1dpdi
‘Disease X’ is a placeholder for an unknown pathogen that could cause a global emergency.
History has taught us that we must anticipate new threats. Failing to prepare leaves the world prepared to fail.
At #WEF24 today, I spoke about @WHO initiatives that are supporting countries to prepare better, including investment in local production, surveillance and development of a generational #PandemicAccord.
Top pharma CEO says preparedness for a new pandemic has not improved https://t.co/TUdKYVxqRt “...ideally we would live in a world where that inter-pandemic preparedness, like we do in defense, like we do in other areas, would continue so we’re ready for the next pandemic.”
Find out why this paper earned “Editor's Choice” status: Praemonitus praemunitus: can we forecast and prepare for future viral disease outbreaks? https://t.co/uL0U4NCxm0
One of @READDI_Inc's foundational steps was to create a landscape assessment of all antiviral drug development work, both active and abandoned, targeting the virus families of high pandemic risk. A huge thank you to SciVida for executing the database. https://t.co/mDpw9vMqBk
Congrats on the progress! This is a significant new addition to the armamentarium of COVID-19 treatments. "How open-source drug discovery could help us in the next pandemic" https://t.co/v6UYStHAIp
“What about Disease X? What is the value of a portfolio of antiviral drugs for a disease that does not yet exist?” @READDI_Inc CEO Jimmy Rosen discussed solutions at the #MIHealthSummit. Thank you @MilkenInstitute for the opportunity! https://t.co/5YMIalELKI
What if it took 100 days to make a safe and effective vaccine against any virus? 💉
Read more about the 100 Days Mission for vaccines from our partners @CEPIvaccines 👇
“We're very focused on pandemic solutions—making broad-spectrum small molecule antiviral drugs affordable and accessible to everybody who needs them, when they need them, where they need them.” — CEO Jimmy Rosen #MIHealthSummit@MilkenInstitute
The paramyxovirus family includes some of the fastest-spreading pathogens in human history—think measles—as well as some of the deadliest. Could this group of viruses spark the next pandemic? @KatherineJWu reports: https://t.co/PYhcyGTy1D
The GAO says “Pandemic antivirals represent what economists call a ‘market failure’—prices do not reflect the benefit these drugs offer to society.” https://t.co/OiT1h06pmI @READDI_Inc is working on a solution: https://t.co/aO7M8bqKei